Moderna’s disclosure this week that its respiratory syncytial virus vaccine prevented most infections in older adults in a clinical trial further sets the stage for a competitive new market ahead of next winter’s cold season.
The company’s stock MRNA gained 3.6% in trading on Wednesday, the day after Moderna said in a news release that its experimental RSV vaccine had an efficacy rate of 83.7% in adults 60 and older. The full data set is expected to be shared at an unnamed medical meeting in the future. There are currently no RSV vaccines for adults or children, but the attention brought to vaccine development, including messenger RNA technology, as a result of the COVID-19 pandemic revitalized interest in RSV vaccines in what could be a $5 billion market. Though RSV causes regular cold symptoms in most people, it’s of particular concern when it comes to infants, who breathe exclusively through their noses, and older adults, who are at a higher risk of developing lung infections or pneumonia.
I have 5 Moderna Covid vaccines. I'll get this one too as soon as I can.
Amazing news